2019
Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study
Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O’Connor M, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Research 2019, 21: 38. PMID: 30850011, PMCID: PMC6408779, DOI: 10.1186/s13058-019-1120-5.Peer-Reviewed Original ResearchConceptsLow-dose tamoxifenMolecular breast imagingBackground parenchymal uptakeOral tamoxifenParenchymal uptakeBreast cancer risk reductionBreast cancer risk factorsEffectiveness of tamoxifenCancer risk factorsCancer risk reductionBreast cancer historyShort-term interventionMean ageCancer historyRisk factorsBreast fibroglandular tissueTamoxifenMolecular breastAverage countStudy participantsSubcutaneous fatPilot studyWomenT-testIntervention
2018
Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices
Ganju A, Suresh A, Stephens J, Palettas M, Burke D, Miles L, Lehman K, Rudesill R, Lustberg M, Bose-Brill S, Ramaswamy B. Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices. Breastfeeding Medicine 2018, 13: 651-656. PMID: 30354228, DOI: 10.1089/bfm.2018.0170.Peer-Reviewed Original ResearchConceptsBreast cancer risk reductionCancer risk reductionBreastfeeding practicesBreast cancerHealthcare providersOhio State University Comprehensive Cancer CenterRisk reductionDuration of breastfeedingClinical research registryPrimary care practicesComprehensive cancer centerAfrican American womenSustain breastfeedingCancer CenterKnowledge of associationsCaucasian womenBreastfeeding benefitsResearch RegistryRecent childbirthLive birthsProtective effectAims/Improved counselingBreastfeedingCare practices
2015
Breast Cancer Risk Reduction, Version 2.2015.
Bevers T, Ward J, Arun B, Colditz G, Cowan K, Daly M, Garber J, Gemignani M, Gradishar W, Jordan J, Korde L, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman R, Loftus L, Mahoney M, Merajver S, Meszoely I, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht M, Visvanathan K, Wallace A, Bergman M, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 880-915. PMID: 26150582, DOI: 10.6004/jnccn.2015.0105.Peer-Reviewed Original Research
2002
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal Of Clinical Oncology 2002, 20: 3328-43. PMID: 12149307, DOI: 10.1200/jco.2002.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer risk reductionUse of tamoxifenCancer risk reductionBreast cancer riskCancer riskASCO Health Services Research CommitteeBreast cancer risk reduction strategiesAromatase inhibitionCancer risk reduction strategiesClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalHigher breast cancer riskUse of raloxifeneCancer-specific survivalHormone replacement therapyBreast cancer incidenceHealth benefitsGreater clinical benefitOverall health benefitsAmerican SocietyOutcomes of interestNet health benefitRisk reduction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply